Clareo Health | A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19
A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
BioNTech SE
With
Pfizer
Age
5–11
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Children 5 through 11 years of age at their first appointment.
Children with at least 1 underlying stable medical condition that increases their risk of severe COVID-19, as listed in the protocol.
You may not be if
Children who have had confirmed COVID-19 within the last 5 months (150 days).
Children who have received a COVID-19 vaccine, either as part of a research study or an approved vaccine, within the last 5 months (150 days).
Children who have received a 2025-2026 seasonal COVID-19 vaccination.
Children with a history of myocarditis or pericarditis.
Children with a previous or current diagnosis of Multisystem Inflammatory Syndrome in Children (MIS-C)
Children with a medical condition wherein they would be considered for a second dose of COVID-19 vaccine to protect against risk of severe COVID-19 based on standard of care.
Refer to the study contact for further eligibility details.
